Immunotech Laboratories, Inc. (Immunotech) is a drug development company that focuses on research and development in the biotechnology field. The Company is also focused on the commercialization of its proprietary proteins known as Irreversible Pepsin Fraction (IPF) ITV-1 for the treatment of debilitating infectious diseases, such as human immunodeficiency virus (HIV) and Hepatitis Type C.

Employees

Sector

Biotechnology & Medical Research

More about the company

Market Cap	60.56L 53.08L 49.06L 45.12L 85.14L 58Cr 86.5L 5.87Cr 2.3Cr 29Cr 2.27Cr 2.22Cr 98Cr	P/E 2008 *	-	P/E 2009	-310x
Enterprise Value	72.46L 63.51L 58.71L 54L 1.02Cr 70Cr 1.04Cr 7.02Cr 2.75Cr 34Cr 2.72Cr 2.66Cr 117.79Cr	EV / Sales 2008 *	-	EV / Sales 2009	-
Free-Float	99.34%	Yield 2008 *	-	Yield 2009	-

22/17/22	Immunotech Laboratories, Inc. Announces Addition of Hongxiang Hui to Advisory Board	CI
22/17/22	Immunotech Laboratories Enters Distribution Agreement for the Territory of the Ukraine; Enters Final Step of Full Commercialization by the BDA Post Phase 3 Approval of ITV-1 for HIV/AIDS	CI
14/17/14	Eco-Petroleum Solutions, Inc. acquired Immunotech Laboratories, Inc..	CI
01/16/01	Immunotech Laboratories, Inc. cancelled the transaction announced on October 1, 2013	CI
21/14/21	Ebola becomes latest stock scam, SEC says	RE
21/14/21	Immunotech Laboratories, Inc. and Immunotech Laboratories, BG Enter into Agreement with Uldic Investment to Market Potential Ebola Virus Disease Treatment in Africa	CI
07/14/07	Immunotech Laboratories, Inc and Immunotech Laboratories, BG. Announces Successful Completion of Phase I and Phase II Field Trials of HIV/AIDS and Hepatitis C Virus Treatment	CI
28/14/28	Immunotech Laboratories, Inc. Announces Completion of Phase I and Phase II Field Trials of Patented Treatment of the HIV/AIDS and Hepatitis C Viruses	CI
01/13/01	Immunotech Laboratories, Inc. announced that it expects to receive funding from World Finance Capital Holdings Inc.	CI
15/13/15	Immunotech Laboratories, Inc. Appoints Blaine Nabors as VP of Business Development	CI
01/13/01	Immunotech Laboratories, Inc. Relocates to New Research & Development Laboratory Facility	CI
21/13/21	Immunotech Laboratories, Inc. Announces Clinical Trials Updates for company's AIDS-HIV 'IPF' Medicines	CI
05/13/05	Immunotech Laboratories, Inc. Appoints Valentin Dimitrov to Board of Directors	CI

Director	Title	Age	Since
Harry Zhabilov CHM	Chairman	59	01/07/2014
Valentin Dimitrov BRD	Director/Board Member	61	04/02/2013

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
IMMUNOTECH LABORATORIES, INC.	-.--%	+80.00%	-	-	1L
ARGENX SE	+0.21%	-0.79%	+53.17%	+57.39%	5.38TCr
WUXI APPTEC CO., LTD.	+5.37%	+3.31%	+50.39%	+83.65%	5.21TCr
INSMED INCORPORATED	-1.20%	-1.94%	+4.35%	+402.68%	2.35TCr
BIONTECH SE	+0.74%	+2.32%	-16.23%	-14.44%	2.31TCr
WUXI BIOLOGICS (CAYMAN) INC.	+0.63%	+0.79%	+37.50%	-5.41%	1.94TCr
GENMAB A/S	-1.18%	-2.97%	+30.12%	-33.30%	1.76TCr
PHARMAESSENTIA CORPORATION	-1.67%	-6.00%	+163.95%	+284.69%	1.52TCr
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+0.99%	+2.17%	+34.80%	+583.22%	1.48TCr
EXELIXIS, INC.	-0.70%	-0.91%	+24.87%	+179.47%	1.41TCr
Average	+0.32%	-1.60%	+42.55%	+170.88%	2.6TCr
Weighted average by Cap.	+1.07%	-1.49%	+42.08%	+134.35%

	*	1 *
Net sales	-	-
Net income	-	-
Net Debt	-	-

Immunotech Laboratories, Inc. Share Price Other OTC

Stocks

IMMB

US45254F2039

Biotechnology & Medical Research

Valuation: Immunotech Laboratories, Inc.

Latest news : Immunotech Laboratories, Inc.

Press Releases: Immunotech Laboratories, Inc.

Managers and Directors: Immunotech Laboratories, Inc.

Bio Therapeutic Drugs

Financials

Company Profile